OFFICIAL LEGAL TITLE
Drug Shortage Compounding Patient Access Act of 2025
FREQUENTLY ASKED QUESTIONS
What is the official ID of this bill?
The official print number for this legislation is 119_HR_5316.
Which chamber initiated this legislation?
This legislation was initiated in the House of Representatives.
When did the legislative process begin?
The process officially started on 2025-09-11.
What are the main provisions?
Key points include:
- Pharmacies can compound drugs in limited quantities for hospitals if the drug is on the shortage list and cannot be obtained otherwise.
- New labeling requirements for compounded drugs include indicating urgent administration and lack of FDA approval.
- Drug manufacturers must report not only manufacturing interruptions but also surges in demand to help prevent shortages.
- Increased transparency regarding drug shortages aims to facilitate quicker responses to market deficiencies.
What is the specific legal status?
The current status is Introduced.
Where can I read the full text of this legislation?
The full official text is available at:
View full text
Who is the primary sponsor?
The primary sponsor is Rep. Harshbarger, Diana [R-TN-1].
What is the latest detailed status?
The latest detailed status is: Referred to the House Committee on Energy and Commerce.
Is this summary verified?
Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.
What is the impact of this bill?
We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.